The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

New England Journal of Medicine

Volumn 344, Issue 17, 2001, Pages 1263-1269

  Lin, Feng Ying C ^a   Ho, Vo Anh ^c   Khiem, Ha Ba ^d   Trach, Dang Duc ^e   Bay, Phan Van ^c   Thanh, Tran Cong ^d   Kossaczka, Zuzana ^a   Bryla, Dolores A ^a   Shiloach, Joseph ^b   Robbins, John B ^a   Schneerson, Rachel ^a   Szu, Shousun C ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c Dong Thap Provincial Hospital   (Viet Nam)

^d NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^e NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE VACCINE; PSEUDOMONAS EXOTOXIN; SODIUM CHLORIDE; TYPHOID VACCINE;

ANTIBODY RESPONSE; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; CONJUGATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; ERYTHEMA; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA TYPHI; TYPHOID FEVER; VIET NAM;

ADP RIBOSE TRANSFERASES; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; EXOTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; TREATMENT OUTCOME; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE; VIRULENCE FACTORS;

EID: 0035953692     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200104263441701     Document Type: Article

References (37)

1. Vaccination against typhoid fever: Present status
2. Multidrug-resistant typhoid in children: Presentation and clinical features
3. Quinolone-resistant Salmonella typhi in Viet Nam: Molecular basis of resistance and clinical response to treatment
4. Typhoid fever in the United States, 1985-1994: Changing risks of international travel and increasing antimicrobial resistance
5. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water
6. Typhoid fever in children
7. Typhoid fever in African and Indian children in Durban
8. Paediatric aspects of the Aberdeen typhoid outbreak
9. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam
10. Typhoid and paratyphoid fever in 192 hospitalized children in Thailand
11. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
12. Typhoid fever in children aged less than 5 years
13. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: Potential use in an epidemic in Tajikistan
14. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report
15. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever
16. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine
17. Typhoid immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
18. A new antigen of B. typhosus
19. Re-examination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi
20. Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen
21. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines
22. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates
23. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: Impact on public health and implications for other polysaccharide-based vaccines
24. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever: Preparation, characterization, and immunogenicity in laboratory animals
25. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi
26. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines
27. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker
28. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam
29. Requirements for Vi polysaccharide typhoid vaccine (requirements for biological substances no. 48)
30. Identification of Salmonella typhi in faecal specimens by an antiserum-agar method
31. Comparative analysis of two rates
32. Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum
33. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever
34. Evaluation of sodium polyanethanol sulfonate as a blood culture additive for recovery of Salmonella typhi and Salmonella paratyphi A
35. Comparative yield of Salmonella typhi from blood and bone marrow cultures in patients with fever of unknown origin
36. Relation between structure and immunologic properties of the Vi capsular polysaccharide
37. O-acetylation affects the binding properties of the carboxyl groups on the Vi bacterial polysaccharide